Idorsia Pharmaceuticals Ltd. has unveiled positive results from the first Phase III study of daridorexant showing that the closely watched drug improved overall sleep and daytime performance of patients with insomnia.
Investors Wake Up To Success Of Idorsia Sleep Drug
Positive Phase III Data For Daridorexant
The Swiss biotech says that a late-stage trial of the dual orexin receptor antagonist daridorexant is the first study to demonstrate an insomnia product that can improve how the patient feels during the day, as well as aiding sleep at night.
